Labor_NP and_CC Cost_NP Requirements_NP of_IN Two_NP Commercial_NP Assays_NP for_IN Qualitative_NP Molecular_NP Detection_NP of_IN Hepatitis_NP C_NP Virus_NP The_DT Bayer_NP transcription-mediated_JJ amplification_NN (_( TMA_NP )_) and_CC the_DT Roche_NP PCR_NP Amplicor_NP version_NN 2.0_CD molecular_JJ assays_NNS for_IN the_DT qualitative_JJ detection_NN of_IN hepatitis_NP C_NP virus_NN were_VBD compared_VBN for_IN cost_NN ,_, hands-on_JJ time_NN ,_, assay_NN duration_NN ,_, and_CC complexity_NN ._SENT The_DT TMA_NP assay_NN compares_VBZ well_RB to_TO PCR_NP and_CC may_MD be_VB especially_RB useful_JJ for_IN laboratories_NNS with_IN large_JJ numbers_NNS of_IN test_NN requests_NNS ._SENT Since_IN the_DT cloning_VBG of_IN the_DT hepatitis_NP C_NP virus_NN (_( HCV_NP )_) genome_NN in_IN 1989_CD ,_, diagnosis_NN of_IN infection_NN has_VBZ been_VBN performed_VBN by_IN various_JJ immunologic_JJ and_CC molecular_JJ genetic_JJ assays_NNS in_IN addition_NN to_TO the_DT traditional_JJ examination_NN of_IN liver_JJR biopsy_NN specimens_NNS ._SENT Direct_JJ amplification_NN of_IN HCV_NP RNA_NP provides_VBZ early_JJ evidence_NN of_IN infection_NN independent_JJ of_IN a_DT patient_NN 's_POS immunological_JJ status_NN and_CC is_VBZ an_DT important_JJ tool_NN in_IN the_DT assessment_NN of_IN viral_JJ clearance_NN and_CC thus_RB response_NN to_TO therapy_NN ._SENT We_PP performed_VBD a_DT time-and-motion_NN study_NN and_CC compared_VBN cost_NN of_IN reagents_NNS and_CC disposables_NNS ,_, labor_NN involved_VBN in_IN testing_NN and_CC instrument_NN maintenance_NN ,_, time_NN to_TO result_VB ,_, and_CC hands-on-time_NN of_IN the_DT Bayer_NP transcription-mediated_JJ amplification_NN (_( TMA_NP )_) assay_NN versus_IN the_DT Roche_NP PCR_NP Amplicor_NP version_NN 2.0_CD ,_, our_PP$ current_JJ standard_JJ protocol_NN ._SENT The_DT Roche_NP PCR_NP assay_NN (_( Roche_NP Molecular_NP Systems_NP ,_, Inc._NP ,_, Pleasanton_NP ,_, Calif._NP )_) utilizes_VBZ reverse_JJ transcription-PCR_NN ._SENT In_IN brief_NN ,_, samples_NNS are_VBP prepared_VBN by_IN precipitation_NN of_IN the_DT viral_JJ RNA_NP and_CC addition_NN of_IN an_DT HCV_NP internal_JJ control_NN RNA_NP for_IN assay_NN quality_NN control_NN ._SENT Subsequently_RB ,_, the_DT target_NN RNA_NP is_VBZ reverse_RB transcribed_VBN and_CC then_RB amplified_VBN with_IN specific_JJ HCV_NP primers_NNS which_WDT are_VBP designed_VBN from_IN the_DT highly_RB conserved_VBN 5_CD '_POS untranslated_JJ region_NN of_IN the_DT viral_JJ genome_NN ._SENT Target-specific_JJ oligonucleotide_NN probes_NNS hybridize_VBP with_IN the_DT amplified_VBN products_NNS ._SENT The_DT presence_NN of_IN a_DT hybridization_NN product_NN is_VBZ established_VBN by_IN colorimetric_JJ analysis_NN on_IN a_DT COBAS_NP AMPLICOR_NP analyzer_NN ._SENT The_DT qualitative_JJ Bayer_NP assay_NN amplifies_VBZ RNA_NP by_IN in_IN vitro_NN transcription_NN of_IN a_DT DNA_NP template_NN ._SENT The_DT viral_JJ nucleic_JJ acids_NNS in_IN the_DT specimen_NN ,_, as_RB well_RB as_IN those_DT of_IN an_DT internal_JJ control_NN ,_, are_VBP hybridized_VBN to_TO capture_VB oligonucleotides_NNS complementary_JJ to_TO highly_RB conserved_VBN HCV_NP 5'-untranslated-region_NN sequences_NNS ._SENT The_DT RNA_NP is_VBZ subsequently_RB captured_VBN on_IN magnetic_JJ microbeads_NNS ._SENT After_IN the_DT addition_NN of_IN primers_NNS ,_, reverse_JJ transcriptase_NN ,_, and_CC T7_JJ RNA_NP polymerase_NN ,_, RNA_NP is_VBZ amplified_VBN from_IN a_DT DNA_NP template_NN during_IN a_DT 1-h_NP incubation_NN at_IN 41.5C_JJ ._SENT Single-stranded_JJ ,_, fluorescently_RB labeled_VBN probes_NNS are_VBP then_RB hybridized_VBN to_TO the_DT RNA_NP amplicons_NNS ,_, whereas_IN unhybridized_JJ probes_NNS are_VBP chemically_RB degraded_VBN ._SENT A_DT Leader_NP HC_NP luminometer_NN (_( GenProbe_NP ,_, San_NP Diego_NP ,_, Calif._NP )_) distinguishes_VBZ the_DT chemiluminescent_JJ signals_NNS of_IN the_DT target_NN sequence_NN in_IN the_DT samples_NNS and_CC the_DT internal_JJ control_NN by_IN differential_JJ light_JJ emission_NN (_( Bayer_NP Diagnostics_NP Division_NP ,_, Norwood_NP ,_, Mass._NP )_) ._SENT We_PP evaluated_VBD 182_CD patient_NN sera_NN by_IN the_DT TMA_NP assay_NN ._SENT The_DT 182_CD samples_NNS included_VBD specimens_NNS sent_VBD to_TO our_PP$ laboratory_NN for_IN HCV_NP enzyme_NN immunoassay_NN ,_, HCV_NP recombinant_JJ immunoblot_NN assay_NN (_( RIBA_NP )_) ,_, and_CC qualitative_JJ or_CC quantitative_JJ HCV_NP PCR_NP by_IN the_DT Roche_NP assay_NN ._SENT We_PP also_RB included_VBD random_JJ specimens_NNS that_WDT were_VBD assessed_VBN for_IN analytes_NNS not_RB related_VBN to_TO HCV_NP ,_, such_JJ as_IN human_JJ immunodeficiency_NN virus_NN ,_, hepatitis_NP A_NP and_CC B_NP viruses_NNS ,_, cytomegalovirus_NN ,_, syphilis_NN organisms_NNS ,_, and_CC rubella_NN and_CC varicella_NN zoster_NN virus_NN ._SENT A_DT side-by-side_NN evaluation_NN of_IN the_DT TMA_NP assay_NN and_CC the_DT PCR_NP assays_NNS was_VBD performed_VBN with_IN 172_CD of_IN 182_CD samples_NNS ,_, with_IN TMA_NP assay_NN runs_VBZ of_IN 24_CD ,_, 54_CD ,_, and_CC 94_CD patient_JJ samples_NNS in_IN comparison_NN with_IN either_DT 10_CD (_( one_CD ring_NN )_) or_CC 22_CD (_( two_CD rings_NNS )_) patient_JJ sample_NN runs_VBZ of_IN the_DT Roche_NP system_NN ._SENT We_PP included_VBD one_CD positive_NN and_CC one_CD negative_JJ control_NN sample_NN in_IN each_DT Roche_NP ring_NN and_CC three_CD positive_NN as_IN well_RB as_IN three_CD negative_JJ calibrators_NNS in_IN each_DT TMA_NP assay_NN run_NN ._SENT Twelve_CD of_IN the_DT 172_CD samples_NNS were_VBD duplicates_NNS for_IN reasons_NNS not_RB related_VBN to_TO the_DT assay_NN ._SENT The_DT remaining_VBG 10_CD (_( of_IN 182_CD )_) samples_NNS were_VBD not_RB directly_RB compared_VBN to_TO the_DT Roche_NP method_NN but_CC were_VBD used_VBN to_TO evaluate_VB the_DT possibility_NN of_IN performing_VBG INNO-LIPA_NP genotyping_NN (_( Innogenetics_NP Inc._NP ,_, Norcross_NP ,_, Ga._NP )_) after_IN the_DT TMA_NP assay_NN ._SENT Our_PP$ study_NN population_NN consisted_VBN of_IN 10_CD samples_NNS with_IN indeterminate_JJ RIBA_NP results_NNS and_CC 65_CD with_IN HCV_NP antibody-positive_NN results_NNS ._SENT Of_IN the_DT 170_CD samples_NNS ,_, 25_CD were_VBD originally_RB sent_VBN for_IN testing_NN by_IN Roche_NP PCR_NP and_CC an_DT additional_JJ 10_CD were_VBD both_DT positive_NN by_IN PCR_NP and_CC subsequently_RB genotyped_JJ by_IN the_DT INNO-LIPA_NP system_NN (_( Innogenetics_NP ,_, Inc._NP )_) ._SENT Sixty_CD were_VBD random_JJ samples_NNS (_( tested_VBN for_IN HCV_NP a_DT priori_NN in_IN the_DT TMA_NP assay_NN and_CC PCR_NP comparison_NN )_) ._SENT A_DT total_NN of_IN 65_CD of_IN 170_CD samples_NNS were_VBD HCV_NP positive_JJ by_IN either_DT qualitative_JJ or_CC quantitative_JJ PCR_NP (_( Roche_NP Amplicor_NP )_) ,_, and_CC 66_CD of_IN 170_CD were_VBD positive_JJ by_IN the_DT TMA_NP assay_NN ._SENT The_DT sample_NN newly_RB identified_VBN as_IN positive_JJ by_IN TMA_NP analysis_NN remained_VBD negative_JJ by_IN qualitative_JJ PCR_NP on_IN repeat_NN testing_NN ._SENT This_DT finding_NN may_MD reflect_VB either_RB a_DT false-positive_JJ result_NN ,_, higher_JJR sensitivity_NN of_IN the_DT TMA_NP assay_NN ,_, or_CC PCR_NP inhibition_NN of_IN this_DT sample_NN ._SENT The_DT sample_NN was_VBD subsequently_RB determined_VBN to_TO be_VB negative_JJ by_IN RIBA_NP (_( Chiron_NP Corporation_NP ,_, Emeryville_NP ,_, Calif._NP )_) ,_, but_CC this_DT is_VBZ a_DT less_RBR sensitive_JJ assay_NN than_IN PCR_NP or_CC the_DT TMA_NP assay_NN ._SENT Therefore_RB ,_, the_DT true_JJ status_NN of_IN this_DT specimen_NN could_MD not_RB be_VB determined_VBN ._SENT Results_NNS were_VBD obtained_VBN for_IN all_DT TMA_NP samples_NNS ,_, whereas_IN two_CD PCR_NP samples_NNS failed_VBD to_TO undergo_VB amplification_NN after_IN several_JJ attempts_NNS ._SENT Results_NNS for_IN the_DT 12_CD samples_NNS that_WDT were_VBD duplicated_VBN in_IN the_DT TMA_NP assay_NN were_VBD entirely_RB equivalent_JJ ._SENT The_DT TMA_NP assay_NN requires_VBZ a_DT sample_NN volume_NN of_IN 500_CD mul_NN ,_, versus_CC 200_CD mul_NN for_IN PCR_NP ._SENT Although_IN the_DT Roche_NP amplified_VBD product_NN can_MD be_VB used_VBN directly_RB ,_, subsequent_JJ genotyping_NN using_VBG the_DT line_NN probe_NN method_NN (_( INNO_NP LiPA_NP HCV_NP II_NP ;_: Innogenetics_NP ,_, Inc._NP )_) from_IN the_DT TMA_NP product_NN is_VBZ possible_JJ only_RB after_IN an_DT additional_JJ amplification_NN ._SENT On_IN the_DT other_JJ hand_NN ,_, the_DT TMA_NP assay_NN is_VBZ very_RB easy_JJ to_TO perform_VB ,_, does_VBZ not_RB require_VB repeated_JJ vortexing_NN as_RB does_VBZ the_DT Roche_NP assay_NN ,_, and_CC requires_VBZ minimal_JJ instrument_NN maintenance_NN ._SENT The_DT time_NN to_TO results_NNS and_CC hands-on_JJ time_NN per_IN sample_NN were_VBD measured_VBN once_RB in_IN each_DT individual_JJ assay_NN setup_NN ._SENT Both_DT are_VBP substantially_RB better_JJR for_IN TMA_NP analysis_NN ,_, even_RB when_WRB a_DT large_JJ number_NN of_IN specimens_NNS is_VBZ tested_VBN ._SENT Consequently_RB ,_, labor_NN costs_NNS are_VBP lower_JJR for_IN the_DT TMA_NP assay_NN ._SENT The_DT general_JJ cost_NN of_IN disposables_NNS is_VBZ also_RB lower_JJR for_IN TMA_NP assay_NN ,_, but_CC these_DT costs_NNS remain_VBP well_RB below_IN $2_NN per_IN reportable_JJ result_NN in_IN both_DT assays_NNS ._SENT Comparing_VBG list_NN prices_NNS for_IN both_DT assays_NNS ,_, the_DT reagent_NN cost_NN of_IN Roche_NP PCR_NP analysis_NN is_VBZ significantly_RB lower_JJR than_IN that_DT of_IN the_DT TMA_NP assay_NN ,_, although_IN manufacturers_NNS '_POS volume_NN discounts_VBZ certainly_RB influence_VB final_JJ pricing_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Detailed_JJ and_CC global_JJ representation_NN of_IN hands-on_JJ and_CC hands-off_JJ (_( h-o_NN )_) time_NN for_IN HCV_NP diagnosis_NN by_IN the_DT Roche_NP PCR_NP Amplicor_NP version_NN 2_CD ._SENT Detailed_JJ and_CC global_JJ representation_NN of_IN hands-on_JJ and_CC hands-off_JJ (_( h-o_NN )_) time_NN for_IN HCV_NP diagnosis_NN by_IN the_DT Roche_NP PCR_NP Amplicor_NP version_NN 2.0_CD assay_NN and_CC the_DT Bayer_NP TMA_NP assay_NN ._SENT "_`` Break_VB "_'' indicates_VBZ the_DT technologists_NNS '_POS time_NN away_RB from_IN the_DT bench_NN ._SENT Neither_DT assay_NN was_VBD delayed_VBN by_IN these_DT breaks_NNS ._SENT The_DT bars_NNS reflect_VBP respective_JJ amounts_NNS of_IN hands-on_JJ and_CC hands-off_JJ time_NN in_IN both_DT assays_NNS ,_, as_RB well_RB as_IN their_PP$ relative_JJ positions_NNS within_IN the_DT assay_NN timelines_NNS ._SENT TTU_NP ,_, test_NN tube_NN unit_NN (_( a_DT fixed_VBN row_NN of_IN 10_CD test_NN tubes_NNS used_VBN in_IN the_DT TMA_NP assay_NN )_) ._SENT In_IN summary_NN ,_, TMA_NP analysis_NN compares_VBZ well_RB to_TO PCR_NP amplification_NN for_IN ease_NN of_IN use_NN and_CC reliability_NN of_IN results_NNS ._SENT Only_RB the_DT Roche_NP PCR_NP test_NN is_VBZ FDA_NP cleared_VBD at_IN this_DT time_NN ._SENT Because_IN larger_JJR numbers_NNS of_IN samples_NNS can_MD be_VB processed_VBN in_IN a_DT shorter_JJR time_NN than_IN for_IN the_DT PCR_NP assay_NN ,_, the_DT TMA_NP assay_NN may_MD be_VB the_DT assay_NN of_IN choice_NN in_IN a_DT laboratory_NN which_WDT requires_VBZ short_JJ turnaround_NN times_NNS and_CC can_MD accept_VB a_DT larger_JJR required_JJ sample_NN volume_NN ._SENT The_DT TMA_NP assay_NN may_MD be_VB especially_RB useful_JJ for_IN laboratories_NNS with_IN large_JJ numbers_NNS of_IN qualitative_JJ HCV_NP diagnostic_JJ requests_NNS ._SENT 